explore -WSS

explore

author：explore 2025-10-02 18:05:42 - browse：421

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： FDA investigates CAR

WSS

It's time to get medical device identifiers over the finish line

Living with Fabry disease, a condition that causes chronic pain

Study: Pain burden is higher in Black NFL players than white ones

NIH fellows want a pay raise. Will that mean less money for grants?

It's time to get medical device identifiers over the finish line

Study: Pain burden is higher in Black NFL players than white ones

explore

explore

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Flagship Pioneering launches a new biotech in two countries

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A new study sees potential in DNA sequencing of infants

Apple is now the first public company to be valued at $3 trillion

A new study sees potential in DNA sequencing of infants

Continuity nursing helped my family in our darkest PICU moments

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Hollywood unions extend contract negotiations for actors

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

leisure time

New research casts further doubt on a common procedure used with IVF

What to know about OceanGate, the company behind the missing Titanic submersible

Pediatric cancer treatments threatened by a new FDA policy

It's time to get medical device identifiers over the finish line

Rep. Raul Ruiz on the physician shortage and more

With clinical trial data readouts, here's how to spot spin

leisure time

hotspot

hotspot

leisure time